MELANOMA PATIENT CONFERENCE, 2023

FRIDAY 17 MARCH 2023

VOCO ST JOHN'S HOTEL, SOLIHULL, BIRMINGHAM B91 1AT
The UK Melanoma Patient Conference was established in 2016 by the founder, Imogen Cheese, who was determined to empower patients. From 2023, the Melanoma Patient Conference will be hosted and supported by Melanoma Focus, a national charity dedicated to providing support and education to melanoma patients and healthcare professionals as well as commissioning research and raising awareness of melanoma, the 5th most common cancer in the UK. Imogen Cheese will continue to curate the programme based on consultation with the patient community and medical professionals to ensure that recent developments in treatments and care remain key.

The conference aims to provide a safe space for patients and carers to interact and network with other patients and carers, expert medical speakers and charities, while hearing about the latest advances in melanoma medicine.
# Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45</td>
<td>Registration and Coffee</td>
</tr>
<tr>
<td>09:10</td>
<td>Welcome Mrs Imogen Cheese, Conference Chair</td>
</tr>
<tr>
<td>09:15</td>
<td><strong>Session One: (New Trials, Treatments &amp; Resources)</strong> Chair: Susanna Daniels</td>
</tr>
<tr>
<td>09:15</td>
<td>VAT Burn campaign (Amy Callaghan, MP)</td>
</tr>
<tr>
<td>09:30</td>
<td>Clinical Trials Update. Innovation &amp; Progress (Dr Pippa Corrie)</td>
</tr>
<tr>
<td>10:00</td>
<td>My Melanoma (Professor Mark Middleton)</td>
</tr>
<tr>
<td>10:20</td>
<td>TILs explained (Dr Andrew Furness)</td>
</tr>
<tr>
<td>10:50</td>
<td>Audience Q&amp;A</td>
</tr>
<tr>
<td>11:05</td>
<td>Refreshments &amp; Networking</td>
</tr>
<tr>
<td>11:30</td>
<td><strong>Session Two: (The Melanoma Landscape)</strong> Chair: Imogen Cheese</td>
</tr>
<tr>
<td>11:30</td>
<td>National melanoma incidence statistics during the Covid-19 pandemic (Dr Zoe Venables)</td>
</tr>
<tr>
<td>11:55</td>
<td>Patient Voice Navigating Challenges (Michelle Richardson)</td>
</tr>
<tr>
<td>12:15</td>
<td>NICE guidelines (Mr Howard Peach)</td>
</tr>
<tr>
<td>12:40</td>
<td>Audience Q&amp;A</td>
</tr>
<tr>
<td>13:00</td>
<td>Lunch Break &amp; Networking</td>
</tr>
<tr>
<td>14:00</td>
<td><strong>Session Three: (Follow up &amp; AI)</strong> Chair: Mr Oliver Cassell</td>
</tr>
<tr>
<td>14:00</td>
<td>Dermatology &amp; AI. What does this mean for the future? (Dr Faisal Dubash)</td>
</tr>
<tr>
<td>14:25</td>
<td>Reconstructive Surgery, Scars and Lymphoedema (Mr Alex Ramsden)</td>
</tr>
<tr>
<td>14:50</td>
<td>Scans for melanoma patients - what when and why? (Dr Oliver Hulson)</td>
</tr>
<tr>
<td>15:15</td>
<td>Audience Q&amp;A</td>
</tr>
<tr>
<td>15:30</td>
<td>Refreshments &amp; Networking</td>
</tr>
<tr>
<td>16:00</td>
<td><strong>Session Four: (Living with Uncertainty)</strong> Chair: Lesley Howells</td>
</tr>
<tr>
<td>16:00</td>
<td>Be the person that matters to you (Lesley Howells)</td>
</tr>
<tr>
<td>16:20</td>
<td>Enduring effects of treatment (Gemma Hewitt)</td>
</tr>
<tr>
<td>17:10</td>
<td>Mood Board Review</td>
</tr>
<tr>
<td>17:25</td>
<td>Close – Conference Chair</td>
</tr>
</tbody>
</table>
As experts in melanoma, Melanoma Focus serves the entire melanoma community including patients, carers, medical professionals and the general public. We strive to shape a better future for melanoma patients. The purpose of Melanoma Focus is to provide support and information for patients, carers and healthcare professionals while commissioning and funding innovative research. Activities are grouped into three main areas:

1. Trusted patient support and information:
   Melanoma Helpline - operated by a team of expert skin cancer nurse specialists, they provide confidential information and emotional support to patient, carers and the general public. Cases of melanoma are increasing and we are also seeing an increase in calls to the Helpline.
   ‘This service is a LIFELINE. I can’t thank you enough. On the occasion of calling I was in despair, anxious and depressed. The nurse was knowledgeable, understanding and quickly into getting to the crux of my problems. She gave me a wonderful sense of comfort. She suggested 3 courses of action which were totally practical and absolutely spot on! I wished I had phoned before rather than mulling over the anxieties’

   Melanoma Patient Conference - we support and host this important annual patient conference which provides a safe space for 150-250 patients and carers to interact and network while hearing about the latest advances in melanoma medicine.
   ‘The conference is a great place to learn more about treatment, both current and future research treatments. It’s also good to talk to other melanoma patients and many long-term friendships are forged’

   Patient Information - a wealth of trusted information in various forms such as videos and animations to which clinical teams are also signposting patients. This supports the complex patient pathway (for melanoma skin cancers and rare forms of melanoma).
   ‘I wish this comprehensive information for patients starting treatment for melanoma had been available when I was diagnosed 6 years ago. It has been written for patients to give as much up to date advice as possible’

   Melanoma TrialFinder - a searchable up-to-date resource explaining clinical trials and to help patients (and medical teams) understand the available potential treatment options.
   ‘It makes a huge amount of sense to have some sort of system that does this and something that we have been after for years, not just in melanoma’
Melanoma skin cancer is the 5th most common cancer in the UK*
Approximately 16,700 people are diagnosed annually which is approximately 46 new cases per day*
1 in 36 males and 1 in 47 females will be diagnosed with melanoma in their lifetime*
Over the last decade, melanoma skin cancer incidence rates have increased by around a third (32%) in the UK. Rates in females have increased by more than a quarter (27%), and rates in males have increased by almost two-fifths (38%)*
In the 15–44 year age group, melanoma is the 2nd most common cancer in males and the 3rd in females (Office for National Statistics)
Since the early 1990s, melanoma skin cancer incidence rates have more than doubled (140%) in the UK. Rates in females have around doubled (106%), and rates in males have almost tripled (186%)*
Yet, 86% of melanomas are preventable*

*CRUK 2016-2018
Oxford Cancer is proud to support this event through a grant donation. Oxford Cancer has had no editorial involvement in the development of the programme or content of this meeting.

This event has been made possible through a grant donation from Bristol Myers Squibb. Bristol Myers Squibb have had no editorial involvement in the development of the programme or content of this meeting.

Novartis UK provided the funding for this event to support the conference costs, the filming and production of the meeting. Novartis UK has had no editorial involvement in the development of the programme, content of this meeting or conference presentations.

Harnessing Immunology to Fight Disease.

Scancell supports this event but has no involvement in the organization of the conference and no involvement in the development of the agenda and conference presentations.

Immunocore is supporting this event but has no involvement in the organization of the conference nor in the development of the agenda and conference presentations.

Pierre Fabre has provided a restricted grant to support this meeting. Pierre Fabre has not had any input into the agenda or content of the meeting.
Endorsing and Supporting Organisations

WELEDA
Since 1921

GINGER PEOPLE

GQ

ALTRUIST
DERMATOLOGIST SUNSCREEN

FIT+KIT

MELANOMA UK

GREAT BRITISH BISCOTTI CO.

SKCIN
www.skcin.org
The MyMelanoma Research Study

MyMelanoma is the largest melanoma research study in the world. It is a partnership between people who have been affected by melanoma, clinicians and researchers.

MyMelanoma is designed to answer the most important unanswered questions in melanoma research, which have been identified by people affected by melanoma.

MyMelanoma is open to anyone who has ever been diagnosed with a melanoma of the skin, or of the mucosal surfaces (e.g. nose, genitals).

Will you join us?
To sign up, or for more information, visit our website: www.mymelanomastudy.org
The SCOPE Study
Melanoma Clinical Trial

Are you due to receive ipilimumab and nivolumab or pembrolizumab checkpoint inhibitor therapy?

The SCOPE study is investigating a new immunotherapy called SCIB1, to see if it can be used safely in melanoma. SCIB1 is a vaccine that contains small pieces of DNA, which are designed to help your immune system fight melanoma. SCIB1 will be injected using a needle-free device.

Patients with melanoma are invited to participate in the SCOPE study if your doctor believes you are eligible for this type of immunotherapy.

For more information, please talk your doctor or you can contact us:

info@scancell.co.uk 01865 582 690  
Chief Investigator: poulam.patel@nottingham.ac.uk

SKCIN are the UK's leading skin cancer awareness charity dedicated to prevention and early detection through educational intervention.

Follow us: @SkcinCharity

A special gift for you!

Love from Melanoma UK

For Delegates of the Melanoma Patient Conference 2023
Pippa Corrie qualified in medicine at Oxford University, having previously undertaken a PhD in anticancer drug development. She has been a Consultant Medical Oncologist at Addenbrooke’s Hospital, Cambridge, since 1997 and is an Affiliated Assistant Professor in the University of Cambridge. She has extensive clinical trials experience and is the UK NIHR National Specialty Co-Lead for Cancer. Pippa is recognised nationally and internationally as a leading melanoma specialist and is Chief Investigator of the MITRE immunotherapy microbiome biomarker study, as well as PREMIUM, evaluating neoadjuvant therapy in BRAF mutant melanoma patients. She is a co-founder and Trustee of Melanoma Focus.

**Dr Pippa Corrie**

Consultant & Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust

Pippa Corrie qualified in medicine at Oxford University, having previously undertaken a PhD in anticancer drug development. She has been a Consultant Medical Oncologist at Addenbrooke’s Hospital, Cambridge, since 1997 and is an Affiliated Assistant Professor in the University of Cambridge. She has extensive clinical trials experience and is the UK NIHR National Specialty Co-Lead for Cancer. Pippa is recognised nationally and internationally as a leading melanoma specialist and is Chief Investigator of the MITRE immunotherapy microbiome biomarker study, as well as PREMIUM, evaluating neoadjuvant therapy in BRAF mutant melanoma patients. She is a co-founder and Trustee of Melanoma Focus.

**Talk Summary**

The treatment of melanoma patients continues to evolve at a rate of knots. In particular, new immunotherapy options are being made available to patients both with advanced and early stages of the disease. In the first part of my talk, I will summarise recent clinical trial results that are changing clinical practice globally, as well as in the UK. In the second part, I will share some of the key new and ongoing studies that are recruiting melanoma patients, to raise awareness and encourage support.
I am a medical oncologist in Oxford where I treat patients with melanoma and other cancers. I’m interested in the development of new drugs to treat cancer, principally immunotherapies. To do this I work with scientists and drug companies to identify drug targets, chose new drugs and design both pre-clinical testing programmes and early clinical trials, with the aim of bringing these trials to patients. More recently I have developed an interest in working with new diagnostic platforms to enable earlier detection of cancer. With expertise in setting up and running clinical trials that place patient needs at their core, I’m delighted to be part of the MyMelanoma team.

My Melanoma

Professor Mark Middleton

Consultant Medical Oncologist
Oxford University Hospitals NHS Foundation Trust

I am a medical oncologist in Oxford where I treat patients with melanoma and other cancers. I’m interested in the development of new drugs to treat cancer, principally immunotherapies. To do this I work with scientists and drug companies to identify drug targets, chose new drugs and design both pre-clinical testing programmes and early clinical trials, with the aim of bringing these trials to patients. More recently I have developed an interest in working with new diagnostic platforms to enable earlier detection of cancer. With expertise in setting up and running clinical trials that place patient needs at their core, I’m delighted to be part of the MyMelanoma team.

Talk Summary

MyMelanoma is a new type of cancer clinical study that learns lessons from the rapid response to the COVID-19 pandemic. It aims to deliver cutting edge research at the scale and pace needed to deliver on melanoma patients’ priorities. We are building the world’s largest database of melanoma patients experiences, health records, and samples to help researchers across the world develop new ways of detecting, treating, and curing melanoma.

To achieve this we need your help. For air traffic controllers, knowing where one plane is useful, but knowing where that plane is relative to all the others, is what helps them manage the skies. Cancer research is similar. It is a combination of understanding both individual melanoma patient experiences and how they compare with others that makes a real difference in research. By signing up to MyMelanoma, you can add your experiences to our collective understanding of the patient experience, improve the data that researchers across the UK have access to, and directly play a role in our push towards curing the disease.
Dr Furness is a Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust. He specialises in the treatment of patients with cancers of the skin and kidney although his research interests are focused on the application of cellular therapy across all solid tumours. He is passionate about broadening the reach of immunotherapy to benefit more patients and is optimistic that cell-based approaches may hold particular promise.

Dr Andrew Furness
Consultant Medical Oncologist
Royal Marsden NHS Foundation Trust

Dr Furness is a Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust. He specialises in the treatment of patients with cancers of the skin and kidney although his research interests are focused on the application of cellular therapy across all solid tumours. He is passionate about broadening the reach of immunotherapy to benefit more patients and is optimistic that cell-based approaches may hold particular promise.

Talk Summary

I will be discussing tumour-infiltrating lymphocyte (TIL) therapy for patients with advanced melanoma. This will include progress to date, practical considerations for patients including associated toxicity, time and travel. Progress to date will be presented as well as current and planned future clinical trials exploring the utility of this approach.
I am a Dermatology Consultant and recently appointed Associate Professor of Clinical Medicine at the Norfolk and Norwich University Hospital. I am the dermatology clinical lead at the National Disease Registration Service (NDRS) and chair the British Association of Dermatologists and NDRS Partnership. My area of research interest is skin cancer epidemiology focusing on analysing large national datasets.

Dr Zoe Venables

Consultant Dermatologist
Norfolk and Norwich University Hospitals NHS Trust

I am a Dermatology Consultant and recently appointed Associate Professor of Clinical Medicine at the Norfolk and Norwich University Hospital. I am the dermatology clinical lead at the National Disease Registration Service (NDRS) and chair the British Association of Dermatologists and NDRS Partnership. My area of research interest is skin cancer epidemiology focusing on analysing large national datasets.

Talk Summary

I have been asked to present our findings on national melanoma incidence during the COVID-19 pandemic. During the pandemic, having access to up-to-date healthcare data became essential to understand the wider effects it was having on our health. The cancer registry in England (National Disease Registration Service) developed the Rapid COVID Registration Dataset which, for the first time, published cancer counts much more rapidly than standard cancer registration. This allowed a better understanding of the effect of the pandemic on our cancer diagnoses and service provision. We report how the melanoma cases reduced during the pandemic and reflect on the long-term consequences.
Michelle Richardson - mum, wife and physiotherapist living for the last 3 and a half years with stage 4 Melanoma, trying to work out a new normal in the whirlwind of an incurable diagnosis and the side effects - physical, cognitive and emotional - of treatment and beyond.

**Patient Voice Navigating Challenges**

Michelle Richardson

**Patient Speaker**

Michelle Richardson – mum, wife and physiotherapist living for the last 3 and a half years with stage 4 Melanoma, trying to work out a new normal in the whirlwind of an incurable diagnosis and the side effects – physical, cognitive and emotional – of treatment and beyond.

**Talk Summary**

I will be talking about my ‘journey’ and looking at the effects of living with an incurable diagnosis. The overwhelming fatigue, side effects of treatment, emotional effects of the diagnosis and constant fear, counselling, management strategies of fear, anxiety and scanxiety. As well as the effects on people close to me (briefly as I am aware they will see this), letting go of control and allowing others to help, returning to work during and after treatment and managing fatigue.
Mr Howard Peach

Consultant Plastic & Reconstructive Surgeon
Leeds Teaching Hospitals NHS Trust

Mr Peach qualified from Bristol in 1989, completed a skin cancer fellowship at the Sydney Melanoma Unit, Australia. 2003 he was appointed to consultant Plastic Surgeon in Leeds and as the regional melanoma MDT lead clinician, has established a comprehensive skin cancer service, including sentinel node biopsy, isolated limb infusion and electrochemotherapy.

He helped develop a national skin cancer fellowship, participates in national and international trials and has organised successful national and international conferences. He continues to develop skin cancer guidelines via Melanoma Focus, Ano-Uro-Genital mucosal melanoma SNB and as an invited NICE committee member the 2022 cutaneous melanoma guidelines.

Talk Summary

On 27th July 2022, NICE released the updated version of its guidelines ‘Melanoma: Assessment and Management’, the previous version had last been updated in July 2015. Over the past 7 years there have been many advances in management and treatment recommendations for patients with melanoma. The 2022 guidelines, tried to reflect these changes and recommended altering several areas of currently accepted standard of care. Some of these areas included genetic testing, surgical strategies and follow-up regimes. The latter in particular has been the most controversial where recommended monitoring has either been upgraded to a more intensive regime, whilst others were downgraded to less intensive surveillance. This presentation will cover the methodology for how the guidelines committee was constituted, the process for developing the guidelines and the rationale for the changes which have been recommended.
Oliver Cassell has been a Consultant Plastic and Reconstructive Surgeon at the Oxford University Hospitals since 2001 and is an Honorary Senior Clinical Lecturer at the University of Oxford. He has a special interest in the management of melanoma, particularly sentinel lymph node biopsy and the management of nodal and cutaneous disease. He has promoted multidisciplinary clinics for the combined discussion and management of advanced and recurrent melanoma.

Mr Oliver Cassell
Consultant Plastic Surgeon
Oxford University Hospitals NHS Foundation Trust

Oliver Cassell has been a Consultant Plastic and Reconstructive Surgeon at the Oxford University Hospitals since 2001 and is an Honorary Senior Clinical Lecturer at the University of Oxford. He has a special interest in the management of melanoma, particularly sentinel lymph node biopsy and the management of nodal and cutaneous disease. He has promoted multidisciplinary clinics for the combined discussion and management of advanced and recurrent melanoma.
Speakers Biographies & Talk Summaries

**Session 3 - Follow up & AI**

**Dermatology & AI. What does this mean for the future?**

**Dr Faisal Dubash**

**Specialist Registrar in Dermatology**  
**NHS Tayside**

Dr Faisal Dubash is a specialist registrar in dermatology at Ninewells Hospital, University of Dundee. He trained at St. George’s Hospital Medical School in London, graduating in 2015. He completed a MSc in Clinical Dermatology at the St. John’s Institute of Dermatology, King’s College London in 2020.

He has presented nationally and internationally. His sub-speciality academic interests, include:  Artificial Intelligence & skin cancer, medical dermatology and cutaneous immunology.

**Talk Summary**

This talk will provide an overview of Artificial Intelligence (AI) in the field of dermatology. Basic concepts in AI will be highlighted, in addition to the use of AI as a diagnostic adjunct in skin cancer diagnosis. Real world challenges in AI development in dermatology need to be overcome before integrating AI into existing skin cancer pathways. The AI skin cancer consortium is a large collaboration of researchers in NHS Tayside and The University of Dundee. Standardising the image pipeline, including community captured images of skin lesions, is important for developing AI algorithms and validating them with datasets, representative of the everyday dermatology workload.
Alex Ramsden is a consultant Plastic Surgeon in Oxford. He has a specialist interest in lymphoedema surgery and ortho-plastic infection. He has been performing supermicrosurgery for lymphoedema in the UK for 10 years and help introduce the techniques following training in Japan. He has completed lymphoedema fellowships in Australia, USA, Sweden and Japan and has been a consultant in Oxford since 2010.

Mr Alex Ramsden
Consultant Plastic Surgeon
Oxford University Hospitals NHS Foundation Trust

Alex Ramsden is a consultant Plastic Surgeon in Oxford. He has a specialist interest in lymphoedema surgery and ortho-plastic infection. He has been performing supermicrosurgery for lymphoedema in the UK for 10 years and help introduce the techniques following training in Japan. He has completed lymphoedema fellowships in Australia, USA, Sweden and Japan and has been a consultant in Oxford since 2010.

Talk Summary

Lymphoedema is a common problem for patients following removal of lymph nodes as part of their cancer treatment. It is estimated that 400,000 people in the UK have lymphoedema but it remains a unrecognised and little known consequence of lymph node surgery. Lymphoedema is a consequence of the damage caused to the lymphatic system at the time of cancer treatment and often results in limb swelling, heaviness and an increased risk of infections. These symptoms are progressive and can become disabling for the patient. The general public and medical professionals are unaware of new and effective surgical treatment for both early and established lymphoedema which can alleviate the symptoms and stop disease progression. I will try to explain the physiology and symptoms of lymphoedema then describe the surgical and non surgical options with updates on the latest developments in this challenging area of medicine.
Dr Olly Hulson is a Consultant Radiologist with a subspecialty interest in oncological and interventional radiology. He supports the melanoma MDT at the Leeds Cancer Centre and is interested in the utility of ultrasound in melanoma diagnostics and therapeutics.

**Dr Oliver Hulson**
Consultant Radiologist
Leeds Teaching Hospitals NHS Trust

Dr Olly Hulson is a Consultant Radiologist with a subspecialty interest in oncological and interventional radiology. He supports the melanoma MDT at the Leeds Cancer Centre and is interested in the utility of ultrasound in melanoma diagnostics and therapeutics.

---

**Talk Summary**

This talk hopes to be an idiot’s guide to imaging investigations in patients with melanoma. We will explore the utility of MRI, CT, PET-CT and ultrasound imaging techniques in local, regional and whole body staging, and look to what the future might hold in the radiological assessment of these patients.
Lesley Howells is a Consultant Clinical Psychologist and the Lead Psychologist for the Maggie's network of twenty-five psychosocial cancer support centres across the UK. Since qualifying in 1991 her research and clinical focus has been families, individuals and couples facing life-changing trauma and transitions, primarily those prompted by changes in physical health (e.g. families with cystic fibrosis, diabetes).

Lesley Howells
Consultant Clinical Psychologist and Lead Psychologist
Maggies U.K.

She is an NHS Accredited Trainer in Advanced Communication, Accredited Mindfulness Teacher and has specialist expertise in the teaching and supervision of NHS Oncology, Haematology and Specialist Palliative Care professionals.

She recently co-authored a chapter for the 2nd edition of Practical Psychodermatology (Wiley 2021) with a Consultant Dermatology colleague in which she introduces ACT based methods for the health care teams to use in the support of people with skin cancers including advanced melanoma.

Talk Summary

As human beings we have evolved by predicting, planning and problem solving to minimise risk and uncertainty, we hate ‘living in limbo’. Yet uncertainty is the daily experience for many people with melanoma and their families, negatively impacting their psychological wellbeing.

This session will look at ways to live the life that matters to you; be the person that matters to you, aligned with your values and despite physical discomfort and uncertain prognosis.
Gemma qualified from Norwich in 2003 in Adult Nursing. She worked in neurology and dermatology before finding her passion for oncology. After spending 10 years on the chemotherapy day unit at the Norfolk and Norwich Hospital, she was recruited as a skin cancer Nurse Specialist. During this time Gemma worked closely with the oncology team, supporting patients with stage 3 and 4 melanoma. This led to a secondment with Macmillan for two years as an Oncology Nurse Specialist where she started a survivorship and late effects clinic for patients following treatment for melanoma. These have been very successful and generated a lot of interest from the professional melanoma community after presenting at the Melanoma Focus conference in 2022. Gemma is now working on her first piece of research, the MELISA study which is collecting the data of patient’s late effects following treatment for stage 3 melanoma. And has recently started her Msc in Skin Management.

Talk Summary

Survivorship focuses on health and the physical, psychological, social and economic issues affecting people after the end of the active treatment for cancer.

Post-treatment cancer survivors range from people having no disease after finishing treatment, people who are continuing to receive treatment to reduce their risk of the cancer coming back and people with well-controlled disease and few symptoms, who receive treatment to manage cancer as a chronic disease. Survivorship care includes issues related to follow up care, the management of late side effects of treatment, the improvement of life and psychological and emotional health.

Nurse-Led Survivorship Clinic’s (NLSC) have been developed, to offer additional psychological support to patients with metastatic melanoma, and to offer a platform to discuss any other physical symptoms or psychosocial concerns they may have. The NLSC is based upon the Macmillan survivorship programme which was introduced in 2014. This session aims to help you recognise some of those thoughts and feelings and channel them into your everyday life.
Evaluation Form

Tell us how we did

Please complete the evaluation form by scanning the QR code
Thank you for your attendance and we looking forward to seeing you next year.

Imogen Cheese
and Melanoma Focus